News
-
-
COMMUNIQUÉ DE PRESSE
Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting
Tharimmune presents positive Phase 1 data for TH104 in treating pruritus in chronic liver disease patients at ACG 2024. No opioid withdrawal effects observed, supporting safety profile -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board
Tharimmune, Inc. appoints Prof. David Jones, an expert in autoimmune liver disease, to its Scientific Advisory Board. Prof. Jones brings valuable insights to advance lead drug candidate TH104 for PBC patients -
-